Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138


The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.

Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS.

Eur J Clin Pharmacol. 2012 May;68(5):689-95. doi: 10.1007/s00228-011-1166-5. Epub 2011 Nov 23.


Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

Orrell C, Cohen K, Conradie F, Zeinecker J, Ive P, Sanne I, Wood R.

Antivir Ther. 2011;16(4):527-34. doi: 10.3851/IMP1780.


Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.

Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM.

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):439-43. doi: 10.1097/QAI.0b013e31819c33a3.


Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.

Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH.

J Clin Pharmacol. 2008 Sep;48(9):1032-40. doi: 10.1177/0091270008321790.


Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.

Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, Charalombous S, Churchyard G, Smith P, Maartens G.

Antivir Ther. 2009;14(5):687-95.


Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.

Sathia L, Obiorah I, Taylor G, Kon O, O'Donoghue M, Gibbins S, Walsh J, Winston A.

AIDS Res Hum Retroviruses. 2008 Jul;24(7):897-901. doi: 10.1089/aid.2007.0277.


The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.

Bienvenu E, Swart M, Dandara C, Ashton M.

Antiviral Res. 2014 Feb;102:44-53. doi: 10.1016/j.antiviral.2013.11.011. Epub 2013 Dec 5.


Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?

Liu J, Chan-Tack KM, Jadhav P, Seo S, Robertson SM, Kraft J, Singer ME, Struble KA, Arya V.

Int J Clin Pharmacol Ther. 2014 Jun;52(6):446-53. doi: 10.5414/CP202079.


Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.

Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson US.

Eur J Clin Pharmacol. 2009 Jan;65(1):71-80. doi: 10.1007/s00228-008-0481-y. Epub 2008 Aug 27.


A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.

Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K; N2R Study Team.

Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114.


Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.

Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO.

Antimicrob Agents Chemother. 2013 Jun;57(6):2780-7. doi: 10.1128/AAC.00191-13. Epub 2013 Apr 9.


Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.

Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Burhenne J, Aklillu E.

Pharmacogenomics. 2015;16(10):1047-64. doi: 10.2217/pgs.15.35. Epub 2015 Apr 1.


CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.

Dhoro M, Zvada S, Ngara B, Nhachi C, Kadzirange G, Chonzi P, Masimirembwa C.

BMC Pharmacol Toxicol. 2015 Mar 27;16:4. doi: 10.1186/s40360-015-0004-2.


Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.

Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E.

Clin Pharmacol Ther. 2011 Sep;90(3):406-13. doi: 10.1038/clpt.2011.129. Epub 2011 Aug 3.


Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.

Mukonzo JK, Okwera A, Nakasujja N, Luzze H, Sebuwufu D, Ogwal-Okeng J, Waako P, Gustafsson LL, Aklillu E.

BMC Infect Dis. 2013 Jun 4;13:261. doi: 10.1186/1471-2334-13-261.


Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.

Matteelli A, Regazzi M, Villani P, De Iaco G, Cusato M, Carvalho AC, Caligaris S, Tomasoni L, Manfrin M, Capone S, Carosi G.

Curr HIV Res. 2007 May;5(3):349-53.


Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.

Luo M, Chapel S, Sevinsky H, Savant I, Cirincione B, Bertz R, Roy A.

Antimicrob Agents Chemother. 2016 May 23;60(6):3676-86. doi: 10.1128/AAC.02678-15. Print 2016 Jun.


Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.

Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F; Adult AIDS Clinical Trials Group A5221 Study Team.

Clin Infect Dis. 2013 Aug;57(4):586-93. doi: 10.1093/cid/cit246. Epub 2013 Apr 16.


Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.

Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F, Valiente R.

J Antimicrob Chemother. 2006 Nov;58(5):1017-23. Epub 2006 Sep 6.


Supplemental Content

Support Center